Skip to main content
PBYI
NASDAQ Life Sciences

Shareholders Reject CEO's Warrant Extension

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$7.17
Mkt Cap
$364.949M
52W Low
$3.03
52W High
$7.898
52W Position info
137% above low
Off High info
9.2% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PBYI has more than doubled off its 52-week low of $3.03.

Summary

Puma Biotechnology shareholders rejected a proposal to extend CEO Alan H. Auerbach's warrant for 2.1 million shares, meaning the warrant will expire as scheduled in October 2026.


Key Events · Corporate Governance and Compliance · PBYI

  • Shareholder Vote Outcome

    Shareholders rejected the proposal to extend CEO Alan H. Auerbach's warrant to purchase 2,116,250 shares at $16.00 per share.

  • Warrant Expiration

    The warrant will now expire on its original date of October 4, 2026, instead of being extended to October 4, 2028.

  • Corporate Governance

    This outcome follows previous proxy filings seeking approval for the extension, indicating a direct shareholder pushback on executive compensation.


Analysis · PBYI · Life Sciences

Shareholders voted against extending CEO Alan H. Auerbach's warrant to purchase 2.1 million shares at $16.00, which was set to expire in October 2026. This rejection, following active solicitation for approval, signals shareholder dissatisfaction with executive compensation or the perceived value of the warrant, preventing a potential future payout for the CEO and avoiding future dilution.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PBYI was trading at $7.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $364.9M. The 52-week trading range was $3.03 to $7.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PBYI - Latest Insights

PBYI
Nov 09, 2026, 4:33 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.40
Real-time Price: $7.05 info
Change: -$1.34 (-16%) info
Market Cap: $364.473M info
PBYI
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.77
Real-time Price: $7.05 info
Change: -$2.72 (-28%) info
Market Cap: $364.473M info
PBYI
Aug 06, 2026, 4:41 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.12
Real-time Price: $7.05 info
Change: -$1.07 (-13%) info
Market Cap: $364.473M info
PBYI
Aug 06, 2026, 4:35 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $8.12
Real-time Price: $7.05 info
Change: -$1.07 (-13%) info
Market Cap: $364.473M info
PBYI
Aug 06, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.12
Real-time Price: $7.05 info
Change: -$1.07 (-13%) info
Market Cap: $364.473M info